The Claim
A computational model predicts that traditional glucose-centric economic models underestimate the cost savings from avoided renal events when SGLT2 inhibitors are prescribed based on cardiovascular risk, resulting in an estimated GBP2.8 billion in national payer savings.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Computational models show that current economic models focused only on blood sugar miss significant cost savings from preventing kidney problems when SGLT2 inhibitors are used in patients with cardiovascular risk, leading to an estimated GBP2.8 billion in savings for national health payers.
See the scientific wording
A computational model predicting outcomes for type 2 diabetes patients shows that traditional glucose-centric economic models fail to capture the cost savings from avoided renal events when SGLT2 inhibitors are used based on cardiovascular risk, leading to an estimated GBP2.8 billion in national payer savings.
When the kidneys filter too much blood due to high sugar and pressure, the tiny tubes inside get damaged over time. A drug that blocks sugar reabsorption in these tubes reduces the workload, which stops the damage before it leads to kidney failure.
What the research says
1 studyTraditional diabetes models only look at blood sugar to decide treatment, but this study shows that using heart and kidney risk instead leads to more use of a helpful drug that prevents kidney damage — saving billions of pounds for the UK health system. The new model catches savings that the old one completely misses.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.